iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Sees Significant Decrease in Short Interest

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 22,477 shares, a decrease of 45.3% from the May 31st total of 41,071 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily volume of 28,094 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Triumph Capital Management bought a new position in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,481 shares of the company’s stock, valued at approximately $35,000.

iShares Genomics Immunology and Healthcare ETF Stock Up 3.9%

Shares of IDNA stock opened at $34.91 on Friday. iShares Genomics Immunology and Healthcare ETF has a 12 month low of $20.56 and a 12 month high of $34.92. The company has a market cap of $198.99 million, a PE ratio of 14.76 and a beta of 0.92. The business’s 50 day moving average is $30.16 and its two-hundred day moving average is $29.27.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.